A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 30, Issue 1, 2007, Pages 51-56

  Kaira, Kyoichi ^a   Tsuchiya, Satoshi ^b   Sunaga, Noriaki ^a   Yanagitani, Noriko ^a   Watanabe, Satoru ^b   Imai, Hisao ^b   Hisada, Takeshi ^a   Ishizuka, Tamotsu ^a   Saito, Ryusei ^b   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY   (Japan)

^b National Nishigunma Hospital   (Japan)

Author keywords

Carboplatin; Chemotherapy; Docetaxel; Nonsmall cell lung cancer; Weekly administration

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DOCETAXEL; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR;

AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART FUNCTION; HUMAN; HYPERSENSITIVITY REACTION; KIDNEY DISEASE; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PERFORMANCE; PHASE 1 CLINICAL TRIAL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; TAXOIDS; TREATMENT OUTCOME;

EID: 33846849272     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000242292.17728.46     Document Type: Article

References (33)

1. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer. A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995;311:899-909.
2. Hutchins LF, Unger JM, Crowley JJ, et al. Under-representation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061-2067.
3. Yee KW, Pater JL, Pho L, et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol. 2003;21:1618-1623.
4. Langer CL, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592. A randomized trial. J Natl Cancer Inst. 2002;94:173-181.
5. Elderly Lung Cancer Vinorelbine Italian Study. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst. 1999;91:66-72.
6. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002;346:92-98.
7. Bonomi PD, Finkelstein DM, Ruckedschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1989;7:1602-1613.
8. Hotta K, Matsuo K, Kiura K, et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:3852-3859.
9. Denis JN, Correa A, Greene AE. An improved synthesis of the Taxol side chain and of RP56976. J Org Chem. 1990;55:1957-1959.
10. Kunitoh H, Watanabe K, Onoshi T, et al. Phase II trial of docetaxel in previously untreated advanced non-small cell lung cancer. J Clin Oncol. 1996;14:1649-1655.
11. Fossella FV, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol. 1994;12:1238-1244.
12. Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol. 1994;12:1232-1237.
13. Fossella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol. 1995;13:645-651.
14. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095-2103.
15. Hainsworth JD, Burris HA 3rd, Erland JB, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998;16:2164-2168.
16. Kaira K, Takise A, Minato K, et al. Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer. Anticancer Drugs. 2005;16:455-460.
17. Greco FA. Docetaxel (Taxotere) administrated in weekly schedules. Semin Oncol. 1999;26(suppl 11):28-31.
18. Georgoulias V, Androulakis N, Dimopoulos AM, et al. Front-line treatment of advanced non-small cell lung cancer with docetaxel and cisplatin: a multicenter phase II study. Ann Oncol. 1998;9:331-334.
19. Zalcberg J, Millward M, Bishop J, et al. Phase II study of docetaxel and cisplatin in advanced non-small cell lung cancer. J Clin Oncol. 1998;16:1948-1953.
20. Le Chevalier T, Monnier A, Douillard JY, et al. Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur J Cancer. 1998;34:2032-2036.
21. Belani CP, Bonomi P, Dobbs TW, et al. Docetaxel and cisplatin in patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II trial. Clin Lung Cancer. 1999;1:144-150.
22. Okamoto H, Watanabe K, Segawa Y, et al. Phase II study of docetaxel and cisplatin in patients with previously untreated metastatic non-small-cell lung cancer. Int J Clin Oncol. 2000;5:316-322.
23. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748-1756.
24. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
25. Giannakakis T, Ziras N, Kakolyris S, et al. Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study. Eur J Cancer. 2000;36:742-747.
26. Kasahara K, Myo S, Iwasa K, et al. A phase I study of carboplatin and docetaxel for advanced non-small cell lung cancer using the continual reassessment method. Jpn J Clin Oncol. 2002;32:512-516.
27. Ando M, Saka H, Ando Y, et al. Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences. Cancer Chemother Pharmacol. 2005;55:552-558.
28. Kearns CM, Belani CP, Erkmen K, et al. Reduced platelet toxicity with a combination of carboplatin and paclitaxel: pharmacodynamic modulation of carboplatin-associated thrombocytopenia. Pro Am Soc Clin Oncol. 1995;14:170.Abstract 364.
29. Macha HN, Gatzemeier U, Betticher DC, et al. Randomized multicenter trial comparing paclitaxel (TAX)/carboplatin (CAR) versus paclitaxel/cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC): results of a planned interim analysis. Pro Am Soc Clin Oncol. 1998;17:465a.Abstract 1789.
30. Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer. 2005;104:2766-2774.
31. Hainsworth JD, Burris HA III, Litchy S, et al. Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer. 2000;89:328-333.
32. Lilenbaum R, Rubin M, Samuel J, et al. A phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status (PS) patients (pts) with advanced non-small cell lung cancer (NSCLC) (Abstract). Proc Am Soc Clin Oncol. 2004;23:627.
33. Ohe Y, Niho S, Kakinuma K, et al. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol. 2004;15:45-50.